Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Slater

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Nucleosides, Nucleotides & Nucleic Acids|October 21, 2003
The regiospecific one-pot phosphorylation of either the 5'- or 2'-hydroxyl in 3'-deoxycytidines without protection: critical role of the basePeter D Howes, Martin J Slater, Katrina Wareing
ACS Medicinal Chemistry Letters|June 18, 2025
Application of Free Energy Perturbation (FEP) Methodology for Predicting the Binding Affinity of Macrocyclic JAK2 Inhibitor Analogues of PacritinibNatércia F Braz, Martin J Slater, Stuart Lang
Combinatorial Chemistry & High Throughput Screening|April 28, 2011
The design and application of target-focused compound librariesC John Harris, Richard D Hill, David W Sheppard, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Paul S Jones, Gail Mills, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2018
Evaluation of neomycin analogues for HIV-1 RRE RNA recognition identifies enhanced activity simplified neamine analoguesBinto Simon, Claire Walmsley, Victoria J Jackson, et al.
Organic Letters|December 6, 2002
Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Seb J Carey, Helene Chaignot, et al.
Organic Letters|December 6, 2002
Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituentsDavid M Andrews, Helene Chaignot, Barry A Coomber, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, David M Andrews, Graham Baker, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, Elizabeth M Amphlett, David M Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Studies on acyl pyrrolidine inhibitors of HCV RNA-dependent RNA polymerase to identify a molecule with replicon antiviral activityGeorge Burton, Thomas W Ku, Thomas J Carr, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Nucleosides, Nucleotides & Nucleic Acids|October 21, 2003
The regiospecific one-pot phosphorylation of either the 5'- or 2'-hydroxyl in 3'-deoxycytidines without protection: critical role of the basePeter D Howes, Martin J Slater, Katrina Wareing
ACS Medicinal Chemistry Letters|June 18, 2025
Application of Free Energy Perturbation (FEP) Methodology for Predicting the Binding Affinity of Macrocyclic JAK2 Inhibitor Analogues of PacritinibNatércia F Braz, Martin J Slater, Stuart Lang
Combinatorial Chemistry & High Throughput Screening|April 28, 2011
The design and application of target-focused compound librariesC John Harris, Richard D Hill, David W Sheppard, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Paul S Jones, Gail Mills, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2018
Evaluation of neomycin analogues for HIV-1 RRE RNA recognition identifies enhanced activity simplified neamine analoguesBinto Simon, Claire Walmsley, Victoria J Jackson, et al.
Organic Letters|December 6, 2002
Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Seb J Carey, Helene Chaignot, et al.
Organic Letters|December 6, 2002
Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituentsDavid M Andrews, Helene Chaignot, Barry A Coomber, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, David M Andrews, Graham Baker, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, Elizabeth M Amphlett, David M Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Studies on acyl pyrrolidine inhibitors of HCV RNA-dependent RNA polymerase to identify a molecule with replicon antiviral activityGeorge Burton, Thomas W Ku, Thomas J Carr, et al.
Pageof 2